These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 12616334)

  • 61. Effects of a 2.5-mg silver acetate lozenge on initial and long-term smoking cessation.
    Hymowitz N; Eckholdt H
    Prev Med; 1996; 25(5):537-46. PubMed ID: 8888321
    [TBL] [Abstract][Full Text] [Related]  

  • 62. A randomised study to assess the nicotine pharmacokinetics of an oral nicotine pouch and two nicotine replacement therapy products.
    Azzopardi D; Ebajemito J; McEwan M; Camacho OM; Thissen J; Hardie G; Voisine R; Mullard G; Cohen Z; Murphy J
    Sci Rep; 2022 Apr; 12(1):6949. PubMed ID: 35484309
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Nicotine absorption and dependence in unlicensed lozenges available over the counter.
    Foulds J; Russell MA; Jarvis MJ; Feyerabend C
    Addiction; 1998 Sep; 93(9):1427-31. PubMed ID: 9926548
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Novel rapid-acting sublingual nicotine tablet as a cigarette substitution strategy.
    Rose JE; Behm FM; Botts TL; Botts DR; Willette PN; Vocci F; McCarty J
    Psychopharmacology (Berl); 2022 Sep; 239(9):2853-2862. PubMed ID: 35768615
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Relating Nicotine Plasma Concentration to Momentary Craving Across Four Nicotine Replacement Therapy Formulations.
    Germovsek E; Hansson A; Kjellsson MC; Perez Ruixo JJ; Westin Å; Soons PA; Vermeulen A; Karlsson MO
    Clin Pharmacol Ther; 2020 Jan; 107(1):238-245. PubMed ID: 31355455
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Pharmacokinetic Characterization of a Prototype Mini Nicotine Lozenge.
    Lai PM; Araga M; Hamilton A; Armogida M
    Adv Ther; 2021 Jul; 38(7):3997-4012. PubMed ID: 34105089
    [TBL] [Abstract][Full Text] [Related]  

  • 67. An Open-label Pilot Study of NicoBloc as a Novel Smoking Cessation Intervention.
    Chichester KR; Sisson ML; Chana SM; Wolford-Clevenger C; Hugley MJ; Hawes ES; Palenski P; Nguyen A; Dahne J; Hendricks PS; Cropsey KL
    J Addict Med; 2023 Jul-Aug 01; 17(4):e269-e277. PubMed ID: 37579108
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Population pharmacokinetic-pharmacodynamic model of craving in an enforced smoking cessation population: indirect response and probabilistic modeling.
    Gomeni R; Teneggi V; Iavarone L; Squassante L; Bye A
    Pharm Res; 2001 Apr; 18(4):537-43. PubMed ID: 11451043
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Effects of nicotine mouth spray on urges to smoke, a randomised clinical trial.
    Hansson A; Hajek P; Perfekt R; Kraiczi H
    BMJ Open; 2012; 2(5):. PubMed ID: 23015605
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Single-Dose Bioequivalence of Two Mini Nicotine Lozenge Formulations.
    Rasmussen SC; Becker WD; Shanga GM
    Clin Pharmacol Drug Dev; 2018 Jun; 7(5):498-505. PubMed ID: 29193747
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Electronic cigarettes: abuse liability, topography and subjective effects.
    Evans SE; Hoffman AC
    Tob Control; 2014 May; 23 Suppl 2(Suppl 2):ii23-9. PubMed ID: 24732159
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Single-Dose and Multiple-Dose Pharmacokinetics of Nicotine 6 mg Gum.
    Hansson A; Rasmussen T; Kraiczi H
    Nicotine Tob Res; 2017 Apr; 19(4):477-483. PubMed ID: 27613939
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Abuse liability assessment of tobacco products including potential reduced exposure products.
    Carter LP; Stitzer ML; Henningfield JE; O'Connor RJ; Cummings KM; Hatsukami DK
    Cancer Epidemiol Biomarkers Prev; 2009 Dec; 18(12):3241-62. PubMed ID: 19959676
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Human Abuse Liability Assessment of Tobacco and Nicotine Products: Approaches for Meeting Current Regulatory Recommendations.
    Vansickel A; Baxter S; Sherwood N; Kong M; Campbell L
    Nicotine Tob Res; 2022 Feb; 24(3):295-305. PubMed ID: 34498698
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Nicotine delivery kinetics and abuse liability.
    Henningfield JE; Keenan RM
    J Consult Clin Psychol; 1993 Oct; 61(5):743-50. PubMed ID: 8245272
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Conference on abuse liability and appeal of tobacco products: conclusions and recommendations.
    Henningfield JE; Hatsukami DK; Zeller M; Peters E
    Drug Alcohol Depend; 2011 Jul; 116(1-3):1-7. PubMed ID: 21376479
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Awareness and Acceptance of Nicotine-free Smoking Intervention Methods (Acetium
    Syrjänen K; Patrakka I; Paloniemi E; Soppi A; Hendolin P; Suovaniemi O
    Anticancer Res; 2023 Nov; 43(11):4961-4968. PubMed ID: 37909990
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Strategies for nicotine replacement therapy.
    Buisson B
    Drug Discov Today; 2003 Sep; 8(17):778-9. PubMed ID: 12946637
    [No Abstract]   [Full Text] [Related]  

  • 79. Foods are differentially associated with subjective effect report questions of abuse liability.
    Schulte EM; Smeal JK; Gearhardt AN
    PLoS One; 2017; 12(8):e0184220. PubMed ID: 28859162
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Naltrexone for the treatment of comorbid tobacco and pornography addiction.
    Capurso NA
    Am J Addict; 2017 Mar; 26(2):115-117. PubMed ID: 28106937
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.